Angiomax (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 59 Pages
|Angiomax(急性冠狀動脈症候群)- 預測與市場分析 Angiomax (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023|
|出版日期: 2014年07月31日||內容資訊: 英文 59 Pages||
GlobalData has released its new PharmaPoint Drug Evaluation report, "Angiomax (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023". The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.
The Medicines Company launched its novel anticoagulant, Angiomax (bivalirudin), in the US in January 2001 following approval by the US FDA in December of the previous year. Bivalirudin was subsequently approved for use in the EU in 2004 under the trade name Angiox. Bivalirudin, a small molecule peptide, is a direct thrombin inhibitor. It is administered intravenously during the acute phase of ACS and is indicated for use in patients undergoing PCI.